ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Stock Price Down 1.5% – What’s Next?

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) shares dropped 1.5% during mid-day trading on Monday . The stock traded as low as $29.85 and last traded at $30.14. Approximately 36,777 shares changed hands during mid-day trading, an increase of 202% from the average daily volume of 12,197 shares. The stock had previously closed at $30.59.

ALPS Medical Breakthroughs ETF Price Performance

The company has a 50-day moving average of $32.06 and a 200-day moving average of $35.66.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

Several institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN lifted its stake in ALPS Medical Breakthroughs ETF by 0.3% in the 4th quarter. Wells Fargo & Company MN now owns 126,721 shares of the company’s stock valued at $4,186,000 after acquiring an additional 334 shares in the last quarter. McGuire Investment Group LLC lifted its stake in ALPS Medical Breakthroughs ETF by 28.1% in the 4th quarter. McGuire Investment Group LLC now owns 10,310 shares of the company’s stock valued at $341,000 after acquiring an additional 2,260 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in ALPS Medical Breakthroughs ETF by 3,789.1% in the 4th quarter. Farther Finance Advisors LLC now owns 4,978 shares of the company’s stock valued at $164,000 after acquiring an additional 4,850 shares in the last quarter. Jane Street Group LLC bought a new stake in ALPS Medical Breakthroughs ETF in the 3rd quarter valued at approximately $366,000. Finally, Bank of America Corp DE lifted its stake in ALPS Medical Breakthroughs ETF by 11.5% in the 4th quarter. Bank of America Corp DE now owns 132,231 shares of the company’s stock valued at $4,368,000 after acquiring an additional 13,658 shares in the last quarter.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.